表位
生物
病毒学
甲型流感病毒
T细胞
人口
CD8型
T细胞受体
免疫原性
免疫优势
病毒
抗原
免疫系统
免疫学
医学
环境卫生
作者
Andrea Nguyen,Hiu Ming Peter Lau,Hannah Sloane,Dhilshan Jayasinghe,Nicole A. Mifsud,Demetra S.M. Chatzileontiadou,Emma J. Grant,Christopher Szeto,Stéphanie Gras
摘要
Abstract Objective Influenza A, B and C viruses (IAV, IBV and ICV, respectively) circulate globally, infecting humans and causing widespread morbidity and mortality. Here, we investigate the T cell response towards an immunodominant IAV epitope, NP 265‐273, and its IBV and ICV homologues, presented by HLA‐A*03:01 molecule expressed in ~ 4% of the global population (~ 300 million people). Methods We assessed the magnitude (tetramer staining) and quality of the CD8 + T cell response (intracellular cytokine staining) towards NP 265‐IAV and described the T cell receptor (TCR) repertoire used to recognise this immunodominant epitope. We next assessed the immunogenicity of NP 265‐IAV homologue peptides from IBV and ICV and the ability of CD8 + T cells to cross‐react towards these homologous peptides. Furthermore, we determined the structures of NP 265‐IAV and NP 323‐IBV peptides in complex with HLA‐A*03:01 by X‐ray crystallography. Results Our study provides a detailed characterisation of the CD8 + T cell response towards NP 265‐IAV and its IBV and ICV homologues. The data revealed a diverse repertoire for NP 265‐IAV that is associated with superior anti‐viral protection. Evidence of cross‐reactivity between the three different influenza virus strain‐derived epitopes was observed, indicating the discovery of a potential vaccination target that is broad enough to cover all three influenza strains. Conclusion We show that while there is a potential to cross‐protect against distinct influenza virus lineages, the T cell response was stronger against the IAV peptide than IBV or ICV, which is an important consideration when choosing targets for future vaccine design.
科研通智能强力驱动
Strongly Powered by AbleSci AI